ADC Therapeutics Q1 net product revenue $20.0M, net loss $0.21/share; cash runway into 2028

ADC Therapeutics SA

2026-Q1 EPS reported -$0.21 revenue$20,851,000

Net product revenue $20.0M (up 15% YoY from $17.4M).
Net loss $33.0M ($0.21/share) vs $38.6M ($0.36/share) in Q1 2025; adjusted net loss $19.7M ($0.13/share).
Cash $231.0M as of Mar 31, 2026; cash runway at least into 2028.
LOTIS-5 Phase 3 topline results expected Q2 2026; full data and LOTIS-7 data by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADC Therapeutics SA reported the first quarter ended March 31, 2026 results: revenue $20.0 million, net income $33.0 million, EPS $0.21 per basic and diluted share.

Period: the first quarter ended March 31, 2026
Revenue: $20.0 million
Net income: $33.0 million
EPS: $0.21 per basic and diluted share
Result: reported results

Exact text from the filing

Updates LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE,

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

ADC Therapeutics SA filing history →

Source: SEC EDGAR

accession 0001628280-26-029524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.